Engineered cryo-shocked tumor cells recruit T cells for lung cancer immunotherapy.
Immune checkpoint blockade has transformed cancer therapy, yet its efficacy against solid tumors remains constrained by poor T cell infiltration and an immunosuppressive tumor microenvironment. Achieving localized and sustained chemokine signaling without systemic immune toxicity remains a central unmet challenge for c...